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OBJECTIVES: Evaluate comparative effectiveness and economic impacts of banked
donor milk for premature infants to support evidence-based decision-making for
implementing a public milk bank managed by a blood bank in the province of
Québec.METHODS:A systematic review of the literaturewas performed to identify
clinical benefits of banked donor milk compared to formulas for reducing compli-
cations in preterm or very low birthweight (VLBW) infants. Epidemiology and costs
of these complications were obtained from provincial databases (Régie de
l’Assurance Maladie du Québec; Ministère de la Santé et des Services Sociaux) to
estimate the economic impact of using banked donor milk in this vulnerable pop-
ulation. Milk bank budget was estimated in the context of the Québec blood bank.
RESULTS: Evidence available indicates that the major benefit associated with the
use of banked donor milk compared to formula in premature or VLBW infants is a
reduction by 70% of the rate of necrotizing enterocolitis (NEC). Based on historical
data, the incidence rate of NEC in the province of Québec, Canada, was of 70 cases
during a one year-period between 2008 and 2009which resulted in total direct costs
of 2010US$5,426,128 for the Québec healthcare system. It is estimated that the use
of banked donor milk in neonatalogy would reduce the number of NEC cases by 49
and the number of fatalities by 12 annually, resulting in potential savings. It is
proposed that implementing a public milk bank in a blood bank setting would
result in economic efficiencies CONCLUSIONS: Findings of the present study un-
derlines the clinical benefits of banked donor milk compared to formulas in reduc-
ing the incidence of NEC in premature infants. Implementing a public milk bank in
a blood bank setting could be clinically and economically beneficial.
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OBJECTIVES: Atypical femoral diaphyseal fracture and long-term alendronate use
may be linked. The protective effect and the risk of atypical femoral fracture of alen-
dronateandotheranti-osteoporosisdrugs inolderTaiwanesewomenwereevaluated.
METHODS: A population-based retrospective cohort was obtained from the 2000 to
2009 Taiwan National Health Insurance (NHI) data. Subjects hospitalized with verte-
bral or hip fracture to 2007 were selected using 2000 as a run-in year to identify inci-
dent osteoporotic fractures. All patients receiving alendronate, raloxifene, calcitonin
salmon, or teriparatide after index fracture diagnosis formed the treated cohort. An
untreated cohort was obtained accordingly. Patients were followed until endpoint
(hospitalization for hip fracture or atypical femoral diaphyseal fracture) or end of
study period. Cox proportional hazards models were used to assess the association
between alendronate and other anti-osteoporosis drugs and fracture risks. RESULTS:
Among the 11,278 patients (mean age, 77 years), 2,425 (21.5%) received alendronate
(mean follow-up, 1228797days), 2,694 (23.9%) received other anti-osteoporosis drugs
(mean follow-up, 1069639days), and6,159 (54.6%) remaineduntreated (mean follow-
up, 1357835 days). Head-to-head comparisons revealed alendronate’s superiority
(HR 0.77, 95% CI 0.62–0.95) over other anti-osteoporosis drugs in hip fracture preven-
tion. The risk of subsequent hip fracture was significantly reduced (adjusted HR 0.27,
95%CI 0.15–0.78) in long-termalendronateusers. Risk of atypical femoral fracturewas
similar for alendronate versus other anti-osteoporosis drugs (adjustedHR 0.49, 95%CI
0.40–1.47). Short- or long-term alendronate usewas not associatedwith higher risk of
atypical femoral fractures.CONCLUSIONS:Alendronate poses no greater risk of atyp-
ical femoral fracture than other agents, and its benefits in reducing hip fracture risk
significantly outweigh this concern.
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OBJECTIVES: This study evaluated the persistent use of psychotropic polyphar-
macy and characterized how well the cross-sectional operational definitions of
polypharmacy used in published pediatric studies accurately identify patients’
prescribed long-term treatment.METHODS:The prevalence of psychotropic polyp-
harmacy was defined as receiving 14 days, 30 days, 60 days, and 90 days of
overlapping psychotropic prescription fills. Descriptive analysis was used to com-
pare the prevalence findings based on Multistate Medicaid data involving children
and adolescents 6 to 18 years of age. A sensitivity analysiswas conducted to further
explore the extent to which the cross-sectional operational definitions of poly-
pharmacy used in published literature identified patients who were prescribed
psychotropic combinations on a long-term basis. RESULTS: Analysis of Multistate
Medicaid data revealed that 218,696 children and adolescents filled at least one
psychotropic prescription in 2005. Of these patients, 22.52% received psychotropic
combinations for 14 consecutive days. The observed rate of polypharmacy
dropped to 21.07% with 30 days overlap criterion and to 16.44% with 60 days
overlap criterion. 25%-60% of patients with polypharmacy in cross-sectional defi-
nitions were likely receiving two or more psychotropic agents on a short-term
basis.. Furthermore, cross-sectional definitions failed to identify a 40% to 70% of
patients on long-term polypharmacy (60 day overlap). CONCLUSIONS: The long-
term use of psychotropic polypharmacy in Medicaid children and adolescents in
this study appeared modest. The comparison between our observations and pre-
vious studies illustrate the considerable problems that arise when comparing rates
of polypharmacy across studies with inconsistent operational definitions.
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OBJECTIVES: To determine the prevalence of potentially inappropriatemedication
(PIM) use among older adults in theUSA in 2007 and compare the prevalence to that
in 1996, and to identify risk factors for PIMuse.METHODS: Primary data sourcewas
the 2007 Medical Expenditure Panel Survey. This is a nationally representative
survey of the U.S. community-dwelling population. Study subjects were those re-
spondents aged 65 or older. A retrospective cohort studywas conducted. PIMswere
identified according to the Zhan criteria. Prevalence rates of the 33 PIMs utilization
bymedications and respondents’ characteristics were determined. Risk factors for
PIM use were examined using logistic regression after controlling for confounding
factors.RESULTS:The 33 PIMsuse on the Zhan list declined between 1996 and 2007.
In 2007, 13.8% (95% confidence interval [CI], 12.5%–15.2%) of the elderly or 5.4 mil-
lion older adults received at least 1 of the 33 PIMs; and 1.5% (95%CI, 1.1%–2.0%) used
at least 1 of the 11 PIMs that should always be avoided. The most commonly
misused medications were propoxyphene, amitriptyline, antihistamines, diaze-
pam, muscle relaxants, gastrointestinal antispasmodics, and indomethacin. High-
risk older patients for PIM use included women, people in the South, persons re-
ceiving more prescriptions, and those who rated their health status as fair and
poor. Comparing to data in 1996, the prevalence of PIMs decreased from 6.9million
to 5.4 million although the top three PIMs remained propoxyphene, amitriptyline
and promethazine. The older people who took at least 1 of the 11 PIMs declined
from 0.84 million to 0.59 million. CONCLUSIONS: The 33 PIMs use in older Ameri-
cans decreased butwas still prevalent in some subgroups and for some drugs. Drug
utilization review for elderly population is still needed.
Individual’s Health – Cost Studies
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OBJECTIVES: The purpose of this study is to describe health service use and related
costs associated with potentially inappropriate prescriptions (PIP) of benzodiaz-
epines (BZD) in the elderly living in the community in the province of Quebec,
Canada. METHODS: The cohort consisted of a representative sample (n2494) of
Quebec’s community-dwelling elderly (65 years of age) respondents of the ESA
survey (Survey on older adult’s mental health, 2006). The cost analysis was carried
out from a healthcare system perspective and the definition of the PIP of benzodi-
azepines was based on Beers’ criteria (Fick, 2003). Multivariate regression analyses
were carried out to assess the influence of PIP of BZD on healthcare costs in the
elderly. RESULTS: 30% (n744) of participants were using BZD and 45% (n331) of
the users received at least one PIP. Higher healthcare costs (14196$ vs. 9992$; p
0.0001) were observed for participants with the presence of PIP of BZD in compar-
ison with those without PIP. When individual and health care system factors were
controlled, health care costs were still higher for BZD users with PIP without being
statistically significant at a 95% level ( (log($))  0.109; IC95: [-0.040, 0.259]; 	 $ :
1180$). Factors associated with higher healthcare costs were gender and physical
health status. CONCLUSIONS: Using both administrative and survey data, this
study provides new data that will help decision makers better understand the
economic impact associated with the inappropriate prescriptions of BZD. The sig-
nificant association between the PIP of BZD and the healthcare costs observed in
the univariate analysis seems to be mainly explained by the patient’s physical
health status. Nonetheless, with the current economic and clinical context, partic-
ular attention should be given to the inappropriate prescriptions of BZD, affecting
45% of users and 14% of the senior population in Québec.
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OBJECTIVES: Themain objective of this study was therefore to examine the cost of
the freematernal health services to the southern part of Ghana and explore factors
that contribute to these costs. METHODS: Available routine financial claim records
for 2009 were used to compile the cost information for the various maternal services
usingacompilation sheet for the threenational insurance schemeaccredited facilities
and the scheme office in the area. The financial cost of antenatal, postnatal, delivery,
abortion and the overall costs of all the maternal health services were obtained by
facility type for both services and drugs. RESULTS: Among other findings, we found
that average cost for Ridge hospital antenatal GH¢14.28(US$9.85), postnatal
GH¢63.54(US$43.82) andnormal deliveriesGH¢51.03(US$35.19)whereas that forAdab-
raka Polyclinic antenatal GH¢15.12(US$10.43), postnatal GH¢24.03(US$16.58) and nor-
mal deliveries GH¢37.64(US$25.96). The results of the study showed that
GH¢1,358,647.98(US$936,998.61) was spent in 2009 for maternity services for Osu-
Klottey sub-metro and this represented about 7.7%of expenditure of theBritishGrant.
The financial cost of antenatal care was GH¢289,094.96(US$199,375.83), postnatal
care was GH¢159,913.34(US$110,285.06) and spontaneous vaginal delivery was
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